Brief: Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and Dementia
05/11/2025 13:31
Nov 5 (Reuters) - Nexalin Technology Inc NXL.O: NEXALIN TECHNOLOGY’S Q-SUBMISSION FOR GEN-2 SYNC ACCEPTED BY U.S. FDA FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND DEMENTIA Source text: ID:nGNE7C10jV Further company coverage: NXL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalin Technology
See all newsBrief: Nexalin Technology Regains Compliance With Nasdaq Minimum Bid Price Requirement Nasdaq Hearings Panel Grants Request For Continued Listing
NASDAQ RESUMED AT 12:48 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:43 PM
NASDAQ RESUMED AT 10:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:24 AM